Burning Rock Biotech Limited (NASDAQ:BNR – Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 120,300 shares, an increase of 183.1% from the September 30th total of 42,500 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 27,100 shares, the short-interest ratio is presently 4.4 days.
Burning Rock Biotech Stock Performance
NASDAQ:BNR opened at $2.82 on Monday. The stock has a market capitalization of $28.89 million, a PE ratio of -0.44 and a beta of 0.13. Burning Rock Biotech has a fifty-two week low of $2.62 and a fifty-two week high of $11.10. The company has a fifty day moving average of $4.05 and a two-hundred day moving average of $6.12.
Burning Rock Biotech (NASDAQ:BNR – Get Free Report) last issued its quarterly earnings results on Thursday, August 22nd. The company reported ($0.14) earnings per share (EPS) for the quarter. Burning Rock Biotech had a negative return on equity of 74.96% and a negative net margin of 111.25%. The firm had revenue of $18.65 million during the quarter.
Institutional Investors Weigh In On Burning Rock Biotech
About Burning Rock Biotech
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Featured Stories
- Five stocks we like better than Burning Rock Biotech
- Investing In Preferred Stock vs. Common Stock
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Investing in Commodities: What Are They? How to Invest in Them
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Grocery Stocks That Are Proving They Are Still Essential
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.